The primary outcome also was analyzed in a prespecified analysis that compared the group receiving 12 weeks of varenicline monotherapy vs the other 3 treatment groups generated by the factorial design. The 52-week abstinence rates for the 4 treatment groups adjusted for site appear inTable 3; there were no significant between-group differences for the standard duration of varenicline monotherapy (12 weeks) and any other treatment group.